Related Experiment Video
Updated: Feb 27, 2026

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
Published on: May 10, 2024
Eosinophilic myocarditis and hypereosinophilic syndrome
Hanane Boussir1, Amine Ghalem1, Nabila Ismaili1
1Department of Cardiology, University Hospital of Mohammed VI, Oujda, MoroccoMorocco.
Insights
Hypereosinophilic syndrome (HES) can cause severe cardiac damage. This case highlights a favorable outcome in a patient with eosinophilic myocarditis and cardiogenic shock through prompt, multi-faceted treatment.
Area of Science:
- Hematology
- Cardiology
- Immunology
Background:
- Hypereosinophilic syndrome (HES) is a rare hematological disorder.
- Cardiac involvement in HES, though uncommon, significantly worsens prognosis.
- Cardiac injury in HES progresses through infiltration, thrombosis, and fibrosis stages.
Purpose of the Study:
- To report a case of hypereosinophilic syndrome with significant cardiac involvement.
- To illustrate the management and outcome of eosinophilic myocarditis in cardiogenic shock.
- To discuss the challenges and therapeutic approaches for cardiac HES.
Main Methods:
- Case report of a 33-year-old female patient.
- Diagnosis of HES with pulmonary, gastrointestinal, and cardiac involvement.
- Treatment included dobutamine, anticoagulation, corticosteroids, beta-blockers, and ACE inhibitors.
Main Results:
- The patient presented with eosinophilic myocarditis and cardiogenic shock.
- A favorable clinical evolution was observed with the implemented treatment regimen.
- This case demonstrates successful management of severe cardiac HES.
Conclusions:
- Cardiac involvement in HES is a critical complication requiring aggressive management.
- Corticosteroids remain a primary treatment, but combination therapies are essential.
- Prompt diagnosis and multidisciplinary treatment can improve outcomes in HES-related cardiac injury.
Abstract:
Hypereosinophilic syndrome (HES) is a heterogeneous group of hematological disorders characterized by a chronic, unexplained hypereosinophilia with tissue damage. Cardiac involvement occurs in ∼20% of patients with HES and represents a major turning point. Cardiac injuries related to eosinophilia are divided into three chronological phases: eosinophilic infiltration, thrombosis, and fibrosis. We report a case of a 33-year-old woman diagnosed with HES, with pulmonary and gastrointestinal involvement and eosinophilic myocarditis in cardiogenic shock. The evolution was favorable with dobutamine, anticoagulation, corticosteroids, and later, β-blockers and angiotensin-converting enzyme inhibitors. Cardiac involvement in HES is rare but carries a poor prognosis. Corticosteroids are considered by many to be the mainstay of treatment. Although new treatments have been suggested, only a few seem promising.
More Related Videos
08:44Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation
Published on: May 30, 2020
05:17Fast and Specific Assessment of the Halogenating Peroxidase Activity in Leukocyte-enriched Blood Samples
Published on: July 28, 2016
Related Concept Videos
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis I: Introduction
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Myocarditis III: Medical Management